VasoRX — Operating Costs

[Scientific Research] Open Philanthropy recommended an investment of $280,000 in VasoRX, a company that has discovered and patented a novel lipid nanoparticle capable of delivering RNA interference medication specifically to the vascular endothelium without targeting other tissues such as liver. The company has also discovered that the technology can be used in combination with a specific RNA to reverse pulmonary hypertension and atherosclerosis in preclinical models. This falls within our focus area of scientific research.